Matthew C. Abramowitz
Papers
1
Total Citations
63
H-Index
1
About
Matthew C. Abramowitz is a leading figure in urologic oncology, whose research has profoundly shaped the management of prostate cancer. His work centers on the critical balance between aggressive treatment and active surveillance for low-risk disease, a paradigm shift that has spared countless men from unnecessary interventions. His landmark 2011 cost-comparison study, cited over 60 times, provided compelling economic evidence that active surveillance is not only safe but also significantly more cost-effective than immediate treatment for low-risk prostate cancer. This analysis helped solidify the role of surveillance as a standard of care, influencing clinical guidelines and patient counseling worldwide. Beyond this seminal work, Abramowitz has contributed extensively to optimizing radiation therapy techniques, including stereotactic body radiotherapy (SBRT) and brachytherapy, aiming to maximize tumor control while minimizing toxicity. His research portfolio, spanning health economics, treatment outcomes, and quality of life, has been instrumental in personalizing prostate cancer care, ensuring that patients receive the right treatment at the right time.
Research Focus
Key Achievements
Top Papers
- 1